Lilly’s STAR Results Show Evista Reduces Breast Cancer Risk; sNDA On Track
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Lilly's Evista and AstraZeneca's Nolvadex each reduce the risk of developing invasive breast cancer by roughly 50%, according to initial results from the National Surgical Adjuvant Breast & Bowel Project's Study of Tamoxifen and Raloxifene, released April 17